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Copper(II) complexes of the Schiff base ligands 2-((5-nitrofuran-2-yl)methyleneamino)
phenol (HL1) and 2-(4-nitrobenzylideneamino)phenol (HL2) were prepared and characterized 
using physicochemical and spectroscopic techniques. In these complexes the Schiff base ligands 
acted as a bidentate donor bound to Cu2+ through the oxygen and nitrogen atoms in the deprotonated 
form. The electron paramagnetic resonance spectra, carried out on [CuCl(L1)(phen)].0.5H2O 
and [CuCl(L2)(phen)].2H2O complexes, showed the presence of only mononuclear forms. The 
Cu2+ complexes and ligands were evaluated for their in vitro trypanocidal activity. The complex 
[CuCl(L1)(phen)].0.5H2O was more active than the free Schiff base and also presented a superior 
effect to benznidazole, the reference drug. The antiproliferative activity of the Schiff bases and 
Cu2+ complexes were evaluated for their effect on seven tumor cell lines and showed a cytostatic 
and in some cases a cytotoxic effect. These compounds also presented binding properties to 
deoxyribonucleic acid (DNA) and moderate ability to quench the intrinsic fluorescence of albumins.
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Introduction
The aldimines, also known as Schiff bases, are 
characterized by the presence of a nitrogen which is 
double bonded to a carbon atom C=N–R (R = H, alkyl 
or aryl).1,2 The Schiff bases are widely used as pigments, 
colorants, catalysts, intermediates in organic synthesis and 
polymer stabilizers. They also exhibit a wide spectrum of 
biological activity, including antifungal, antiproliferative, 
anti-inflammatory, antiviral, antipyretic and antiparasitic.2 
In this work we are interested in the antiparasitic and 
antiproliferative activities of the nitro-derivative Schiff 
bases 2-((5-nitrofuran-2-yl)methyleneamino)phenol (HL1) 
and 2-(4-nitrobenzylideneamino)phenol (HL2) which were 
prepared using a microwave-assisted approach (Figure 1).3
Chagas disease is a neglected tropical illness caused by 
Trypanosoma cruzi which affects approximately 7 million 
people worldwide, representing a serious public health 
problem.4 The only two drugs used to treat this disease 
are the nitrofurane derivate nifurtimox (Nfx, 3-methyl-4-
[(5-nitrofurfurylidene)amino]thiomorpholine-1,1-dioxide) 
and the nitroimidazole drug benznidazole (Bnz, 2-nitro-N-
(phenylmethyl)-1H-imidazole-1-acetamide) (see Figure 1), 
both of which lead to severe side effects, require long term 
treatment and are of limited efficacy especially in the chronic 
phase of the disease. Therefore, the development of more 
potent and selective new anti-T. cruzi drugs candidates is 
irrefutable.
In this work we are especially interested in the 
anti-T. cruzi activity of the Schiff base HL1, which is 
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a nitrofurane derivative as is Nfx, thus we prepared the 
nitrobenzene derivative HL2 for comparison. We also 
prepared the Cu2+ complexes of both nitro derivatives, since 
the complex can be more active than the free ligand or the 
complex may activate the ligand as a cytotoxic agent and 
decrease the cell resistance to the drug. Some side effects 
caused by ligands can also be reduced by complexation.5 
The 1,10-phenanthroline coligand was introduced since 
bidentate nitrogen donor ligands have proven to be more 
active than monodentate ligands like pyridine, against 
microorganisms.6
Metabolic pathways of kinetoplastid parasites, such 
as Trypanosoma, are similar to those present in tumor 
cells and produce a correlation between antitrypanosomal 
and anti-tumor activities.7 In addition, it has been 
proposed that compounds that efficiently interact with 
deoxyribonucleic acid (DNA) in an intercalative mode 
could also show antitrypanosomal activity.7 Thus, in this 
work, we also evaluated the antiproliferative activities 
of the Schiff base ligands and their Cu2+ complexes and 
studied their interaction with DNA and proteins, and the 
complexes’ ability to displace ethidium bromide (EB) from 
the DNA-EB complex.
The study of the interaction to DNA for anti-T. cruzi 
candidates is very important, since the mitochondrial 
and the nuclear DNA of the Tripanosoma are targets 
for anti-T. cruzi drugs.8 Furthermore, DNA are the most 
important target for antitumoral drugs, and different types 
of interactions between small molecules and DNA are 
possible: these can often cause DNA damage in cancer 
cells, blocking the division of cancer cells and resulting 
in cell death.9
The study of the interaction between small molecules 
and proteins reveals important information about the 
binding mechanism, binding constant, mode and site.10,11 
Serum albumin is one of the most studied proteins and is the 
most abundant in plasma, representing approximately 60% 
of the blood-plasma.12 Albumins have many physiological 
functions and the most important property of these proteins 
is the ability to deposit and transport many compounds.13
In this work, the binding properties of the free Schiff 
bases and their Cu2+ complexes to DNA and the competitive 
binding with ethidium bromide were investigated using 
ultraviolet-visible (UV-Vis) and fluorescence spectroscopy 
respectively, and the interaction of these complexes with 
bovine and human serum albumins (BSA and HSA) was 
also investigated, using the proteins’ intrinsic fluorescence.
Experimental
Materials and physical measurements
All reagents used in the experiments were obtained 
from commercial sources and used without purification. 
The reagents 4-nitrobenzaldehyde, 5-nitro-2-furaldehyde, 
2-aminophenol ,  calf- thymus DNA (CT-DNA), 
ethidium bromide (EB) and [CuCl2(phen)] were purchased 
from Sigma-Aldrich.
The measurement of the free ligands melting point 
(uncorrected) was carried out using an MQAPF-302 
apparatus.  Infrared spectra  were recorded on 
a PerkinElmer Spectrum One spectrophotometer. 
Nuclear magnetic resonance (NMR) spectra were recorded 
on a Bruker Avance DRX-200 spectrometer. Chemical shifts 
were reported in d units downfield from tetramethylsilane 
(TMS) and J values were given in Hz. Elemental analyses 
were performed using a CHN PerkinElmer 2400 apparatus.
The elemental analyses of the complexes were 
Figure 1. Structures of (a) nifurtimox; (b) benznidazole; (c) 2-((5-nitrofuran-2-yl)methyleneamino)phenol (HL1); (d) 2-(4-nitrobenzylideneamino)
phenol (HL2).
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performed on a CE Instruments model EA 1110. 
Molar conductivity measurements were performed in 
dimethylformamide (DMF) solutions, 1.0 × 10-3 mol L-1 
concentration, using a Quimis conductivity meter (Q405M 
model). The infrared (IR) spectra were acquired on a 
Mattson Instruments Galaxy 3000 spectrophotometer using 
KBr pellets. X-band electron paramagnetic resonance (EPR) 
spectra were obtained with a Bruker ESP300E spectrometer 
with a modulation frequency of 100 kHz and a modulation 
amplitude of 1 mT. A frozen mixture of methanol and 
dimethyl sulfoxide (DMSO) solutions of the complexes 
(1 mmol L-1) were measured at liquid N2 temperature (77 K) 
in Teflon tubes with a 3 mm internal diameter. A Hewlett 
Packard 8451-A UV-Vis spectrophotometer was used to 
obtain UV-Vis spectra with a 1.00 cm quartz cell. Steady 
state fluorescence measurements were performed on a 
Varian-Agilent Cary Eclipse spectrophotometer.
A DNA stock solution was prepared by diluting 
CT-DNA into a 20 mmol L-1 phosphate buffer at pH 7.4 as 
well as the ethidium bromide, BSA and HSA solutions. A 
1.0 × 10-3 mol L-1 dimethyl sulfoxide (DMSO) solution of 
the Schiff bases and Cu2+ complexes were prepared and then 
diluted in a phosphate buffer at pH 7.4, thus the percentage 
of DMSO was equal to 1% (v/v) in solution.
Synthesis
Synthesis of the ligands
Schiff bases 2-((5-nitrofuran-2-yl)methyleneamino)
phenol (HL1) and 2-(4-nitrobenzylideneamino)phenol (HL2) 
were obtained using microwave-assisted condensation on 
the corresponding aldehydes and aromatic amines. The 
reagents were dissolved in absolute ethanol and the resulting 
solutions were irradiated in a CEM Discover reactor for 
2 minutes. After the reactions were completed, the products 
were isolated by recrystallization. The compounds were 
characterized by IR, NMR (1H and 13C), and elemental 
analysis. Although the structures of these ligands have been 
noted in the literature,3,14 a complete characterization of 
these cannot be found and so was described here and in the 
Supplementary Information section.
2-((5-Nitrofuran-2-yl)methyleneamino)phenol (HL1)
Yield: 84%; m.p.: 170 oC (dec); IR (KBr) n / cm-1 3357, 
3154, 1618, 1585, 1568, 1527, 1487, 1471, 1455, 1397, 
1351, 1242, 1168, 1150, 1110, 1018, 971, 956, 941, 884, 
821, 804, 760, 749, 739; 1H NMR (200 MHz, DMSO-d6) 
6.84 (t, 1H, J4,3, J4,5 7.8 Hz, H4), 6.94 (d, 1H, J6,5 7.8 Hz, 
H6), 7.14 (t, 1H, J5,4, J5,6 7.8 Hz, H5), 7.28 (d, 1H, J3,4 7.8 Hz, 
H3), 7.49 (d, 1H, J9,10 3.9 Hz, H9), 7.81 (d, 1H, J10,9 3.9 Hz, 
H10), 8.74 (s, 1H, H7), 9.50 (s, 1H, OH); 13C NMR (50 MHz, 
DMSO-d6) 114.4, 116.6, 116.8 (C3, C9, C10), 119.6, 120.9 
(C4, C6), 129.0 (C5), 136.4 (C2), 146.4 (C7), 151.7, 152.2, 
153.7 (C1, C8, C11); elemental analysis for (C11H8N2O4) 
calcd. (%): C 56.90, H 3.47, N 12.06; found (%): C 56.90, 
H 3.60, N 12.10.
2-(4-Nitrobenzylideneamino)phenol (HL2)
Yield: 84%; m.p.: 159-160 oC; IR (KBr) n / cm-1 3321, 
1625, 1587, 1514, 1478, 1374, 1341, 1316, 1284, 1231, 
1190, 1169, 1142, 1101, 1028, 1009, 965, 940, 849, 836, 
787, 757, 730, 683, 671; 1H NMR (200 MHz, DMSO-d6) 
6.85 (t, 1H, J4,3, J4,5 7.5 Hz, H4), 6.94 (d, 1H, J6,5 8.1 Hz, 
H6), 7.14 (t, 1H, J5,4, J5,6 7.5 Hz, H5), 7.29 (d, 1H, J3,4 7.5 Hz, 
H3), 8.21-8.41 (m, 4H, H9, H10), 8.88 (s, 1H, H7), 9.26 
(br, 1H, OH); 13C NMR (50 MHz, DMSO-d6) 116.4 (C3), 
119.3, 119.5 (C4, C6), 123.8 (C10), 128.6 (C5), 129.8 (C9), 
136.9, 142.0 (C2, C8), 148.6, 151.9 (C1, C11), 156.9 (C7); 
elemental analysis for (C13H10N2O3) calcd. (%): C 64.46, 
H 4.16, N 11.56; found (%): C 64.50, H 4.20, N 11.60.
Synthesis of the complexes
The complexes were obtained by dissolving 0.31 mmol 
of the [CuCl2(phen)] in 50 mL of methanol together with 
gentle heating and stirring. After that 0.31 mmol of HL1 or 
HL2 was added. The mixture was stirred at room temperature 
for 24 h. The solution volume was reduced using a rotational 
evaporator. The solids which precipitated were filtered and 
washed with diethyl ether and dried in vacuum.
[CuCl(L1)(phen)].0.5H2O (1)
Green solid; yield: 44%; elemental analysis for 
(C23H18ClCuN4O4.5) calcd. (%): C 53.0, H 3.3, N 10.8; 
found (%): C 52.6, H 3.1, N 10.7; molar conductivity 
(1 × 10-3 mol L-1, DMF): 47 µS cm-1; IR (KBr) n / cm-1 
1240 m n(CO), 1582 s n(C=N), 1516 m nas(NO2), 
1348 m ns(NO2).
[CuCl(L2)(phen)].2H2O (2)
Green solid; yield: 41%; elemental analysis for 
(C25H22ClCuN4O5) calcd. (%): C 53.9, H 4.0, N 10.0; 
found (%): C 54.2, H 3.8, N 9.9; molar conductivity 
(1 × 10-3 mol L-1, DMF): 35 µS cm-1; IR (KBr) n / cm-1 
1224 w n(CO), 1598 m n(C=N), 1520 s nas(NO2), 
1346 s ns(NO2).
Anti-Trypanosoma cruzi activity
Parasites
The Y strain of T. cruzi was used throughout the 
experiments. Bloodstream forms were harvested by heart 
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puncture from T. cruzi-infected Swiss mice at the peak of 
parasitemia.15 In order to carry out the trypanocidal analysis 
for the in vitro analysis on trypomastigotes, the parasites 
were incubated at 37 °C in the presence of increasing doses 
(0-200 µmol L-1) of each compound diluted in Dulbecco’s 
modified medium supplemented with 5% fetal bovine 
serum and 1 mmol L-1 L-glutamine (DMES).16 After 24 h, 
death rates were determined by light microscopy through 
the direct quantification of live parasites using a Neubauer 
chamber, and the drug concentration value that reduces 
by 50% the number of live parasites (EC50) were then 
calculated as reported.17
Mammalian cell cultures and toxicity assays
Primary cultures of embryonic cardiomyocytes 
(CM) were obtained following the previously described 
method.18 After purification, the CM were seeded at a 
density of 0.1 × 106 cells per well into 24-well culture 
plates, or 0.05 × 106 cell per well into 96-well microplates, 
containing gelatin-coated cover slips and sustained in 
Dulbecco’s modified medium supplemented with 10% 
horse serum, 5% fetal bovine serum, 2.5 mM CaCl2, 1 mM 
L-glutamine and 2% chicken embryo extract (DMEM). 
All procedures are in accordance with the guidelines 
established by the FIOCRUZ Committee of Ethics for the 
Use of Animals (License 0099/01). All the cultures were 
maintained at 37 °C in a 5% CO2 atmosphere, and the 
assays were run at least three times in duplicate. In order 
to rule out toxic effects of the compounds on mammalian 
host cells, uninfected CMs were incubated for 24 h at 
37 °C in presence or absence of the compounds (up to 
200 µmol L-1) diluted in DMEM, then their morphology 
evaluated by light microscopy and the cell viability 
measured by the  3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) colorimetric assay.19 
The absorbance was measured at 490 nm wavelength 
with a spectrophotometer (VersaMax tunable, Molecular 
Devices, USA) allowing the determination of the drug 
concentration value that reduces by 50% the cellular 
viability (LC50) and the respective selective indexes 
(SI = LC50/EC50).
Antproliferative activity
Human tumor cell lines U251 (glioma), MCF-7 (breast), 
NCI-ADR/RES (ovarian expressing a resistant phenotype to 
adryamycin), 786-0 (kidney), NCI-H460 (lung, non-small 
cells), PC-3 (prostate), HT-29 (colon), and the normal 
cell line HACaT were kindly provided by the Frederick 
Cancer Research & Development Center-the National 
Cancer Institute- Frederick, MA, USA. Stock cultures were 
grown in RPMI 1640 (GIBCO BRL, Life Technologies) 
supplemented by 5% of fetal bovine serum, penicillin 
(final concentration of 1 mg mL-1) and streptomycin (final 
concentration of 200 U mL-1).20-22 Cells in 96-well plates 
(100 µL cells per well) were exposed to the Schiff bases 
and complexes (0.25-250 µg mL-1) for 48 h at 37 oC and 5% 
CO2. After this, cells were fixed with 50% trichloroacetic 
acid and submitted to sulforhodamine B assay for cell 
proliferation quantification at 540 nm.23 The compound 
concentration that inhibits cell growth by 50% (IC50) was 
determined through non-linear regression analysis using 
Origin 7.5 software (OriginLab Corporation). Doxorubicin 
was used as a reference drug. The results presented are 
from two independent experiments, each one carried out 
in triplicate.
DNA binding studies
The stock solution of CT-DNA gave a ratio of UV 
absorbance at 260 and 280 nm (A260/A280) of 1.82, 
indicating that DNA was sufficiently free of protein 
contamination.24 The DNA concentration was determined 
by the UV absorbance at λmax 260 nm after 1:20 dilution 
using e = 6,600 L mol-1 cm-1.25
The interaction of the complexes with CT-DNA was 
studied using UV spectroscopy in order to investigate the 
possible binding modes to CT-DNA and to calculate the 
binding constant (Kb). The spectra were recorded using a 
phosphate buffer and 1% DMSO (v/v) in the 200-800 nm 
range. In the UV titration experiments, the spectra of 
each compound, in the presence of CT-DNA, were 
recorded for a constant compound concentration in diverse 
[CT-DNA]/[compound] mixing ratio (r). The Kb values 
were obtained by monitoring absorbance changes in 
the compounds’ spectra at 307, 433, 269 and 436 nm, 
respectively, for HL1, HL2, complexes 1 and 2, with 
increasing concentrations of CT-DNA, according to 
equation 1:26
[DNA]/(εa – εf) = [DNA]/(εb − εf) + 1/[Kb(εb − εf)] (1)
where [DNA] is the DNA concentration in base pairs, εa, 
εf and εb correspond to the apparent, free, and fully bound 
complex absorption coefficients (no absorption change with 
further addition of DNA), respectively. Kb was calculated 
by the slope ratio to the y-intercept in plots [DNA]/(εa − εf) 
versus [DNA].
The competitive studies with ethidium bromide (EB) 
were investigated using fluorescence spectroscopy in order 
to examine the complexes ability to displace EB from the 
CT-DNA-EB complex.27 A solution containing 10 µmol L-1 
of CT-DNA and 15 µmol L-1 of EB was prepared in a 
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phosphate buffer, pH 7.4. The influence of the addition of 
each compound to the CT-DNA-EB complex solution was 
obtained by monitoring the variation in the fluorescence 
emission spectra with λexc = 545 nm at 298 K. Each 
compound aliquot of 2.9 µmol L-1 was added separately 
to 3.00 mL of the CT-DNA-EB complex and the resulting 
fluorescence spectrum was recorded after 5 minutes of 
each addition. The CT-DNA-EB fluorescence quenching, 
in the presence of the Schiff bases and their copper(II) 
complexes, was analyzed according to the Stern-Volmer 
equation (equation 2):
Fo/F = 1 + KSV[Q] (2)
where F and F0 are the relative fluorescence intensities 
of DNA in the presence or absence of the quencher, 
respectively (F0 is taken to be always 100%), [Q] is the 
concentration of the quencher and Ksv is the Stern-Volmer 
quenching constant.
Albumin binding studies
Quenching measurements were taken in 3 mL of 
2 × 10-6 mol L-1 BSA and HSA in a 20 mmol L-1 phosphate 
buffer at pH 7.4. The albumin solutions were titrated by 
successive additions of the ligands and complexes solutions. 
The fluorescence emission spectra were measured using 
an excitation wavelength of 285 and 280 nm, for BSA and 
HSA, respectively. Experiments were performed at 310 K 
and pH 7.4.
The albumins’ fluorescence quenching in the presence 
of the Schiff bases and their copper(II) complexes, at 310 K, 
was analyzed according to the Stern-Volmer equation 
(equation 2). Ksv is the Stern-Volmer quenching constant. 
It is related to the bimolecular quenching constant, kq, and 
the lifetime in the absence of the quencher, τ0, in the case 
of collisional quenching processes resulting from diffusive 
encounters between the fluorophore and the quencher 
during the lifetime of the excited state. In the case of static 
quenching (formation of a non-fluorescent ground-state 
complex) Ksv is the association constant.28
In case of collisional quenching, the bimolecular 
quenching rate constants (kq) are calculated using 
equation 3 and considering that the fluorescence lifetime 
of albumins (τo) are 10-8 s:29
KSV = kqτo (3)
It is important to have in mind that a kq near 
1 × 1010 L mol-1 s-1 is the largest possible value in aqueous 
solution. The magnitude of KSV sometimes is used to show 
that collisional quenching cannot account for the decrease 
in fluorescence intensity. This is the case if the apparent kq 
obtained from equation 3 is much greater than the diffusion 
limited value of 1 × 1010 L mol-1 s-1.
Results and Discussion
Microanalyses and molar conductivity studies
Microanalyses  suggested the formation of 
[CuCl(L1)(phen)].0.5H2O (1) and [CuCl(L2)(phen)].2H2O (2), 
where L1 and L2 represents the deprotonated Schiff base 
ligands coordinated to Cu2+ in a bidentade mode and phen 
represents the 1,10-phenanthroline coligand. The molar 
conductivity data revealed that the complexes 1 and 2 
were non electrolytes in accordance with the proposed 
formulations and the deprotonation of the ligands.
Infrared and electronic spectra
In the HL1 and HL2 infrared spectra an absorption 
band at 3357 and 3321 cm-1, respectively, attributed to the 
stretching of the phenolic ring OH bond was observed. In 
the spectra of the Cu2+ complexes an OH stretching band 
can also be observed due to the presence of the hydration 
water in the structure of the complexes. The band assigned 
to the CO stretching appeared at 1242 and 1231 cm-1 in the 
spectra of the free HL1 and HL2, respectively, and shifted 
to 1240 and 1224 cm-1 in the complexes 1 and 2 spectra, 
indicating that the oxygen was coordinated to the copper. 
Likewise, the band assigned to C=N stretching appeared 
at 1618 and 1625 cm-1 in the free HL1 and HL2 spectra, 
respectively, and shifted to 1582 and 1598 cm-1 in the 
complexes 1 and 2 spectra, indicating the involvement of 
the azomethine nitrogen in coordination.30 Two absorption 
bands were observed in 1527 and 1351 and 1514 and 
1341 cm-1 in the HL1 and HL2 spectra, respectively, and this 
was attributed to the asymmetric and symmetric stretching 
of NO2 group, respectively. In the Cu2+ complexes spectra 
these bands were observed at 1516 and 1348 cm-1 and 1520 
and 1346 cm-1 for 1 and 2, respectively.
The 1,10-phenanthroline out-of-plane vibration of the 
heterocyclic ring hydrogen atoms, appeared at 856 and 
740 cm-1 in the phen spectrum and could be identified 
at 856 and 752 cm-1 in the Cu2+ complexes spectra (see 
Supplementary Information section).31
Electronic spectra of HL1, HL2, complex 1 and 2 
showed a strong absorption band at 282, 283, 282 
and 284 nm respectively, which was attributed to 
the π–π* transition of the carbonyl group.31 After 
complexation, a strong absorption band at 514 and 476 nm 
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for complex 1 and 2, respectively, was observed. This was 
associated to the charge transfer of the Cu2+-ligand. The 
d-d transition of Cu2+, initially observed at 747 nm for the 
[CuCl2(phen)] precursor, presented bathochromic shift after 
complexation, moving to 708 and 740 nm for complex 1 
and 2, respectively, thus indicating greater complex stability 
(see Supplementary Information section).
EPR spectra of the Cu2+ complexes
The EPR spectra of the complexes were obtained, at 
77 K, in a 1:1 mixture of methanol and DMSO solutions to 
ensure the same solvent for both complexes since 1 is more 
soluble in DMSO and 2 in MeOH. The complexes 1 and 2 
exhibited similar spectra characteristic of complexes with 
axial symmetry, and no indication of binuclear complex. The 
g
ll
 region clearly demonstrates the presence of two species, 
i.e., two different Cu2+ sites for both complexes. The two 
sets of hyperfine lines in the parallel region are indicated 
in Figure 2, and Table 1 also shows the EPR parameters of 
these two species. It was observed that the complexes 1 and 
2 exhibit the same EPR parameters in frozen solution.
Comparing the EPR parameters of the two species in 
Table 1, with those of the precursor [CuCl2(phen)], it is 
observed that one of the species has the same parameters as 
the precursor. This suggests that the complexes dissociated 
in solution forming a mixture of the precursor and the Schiff 
bases complexes. 
The insert in Figure 2 shows the second derivative of the 
spectrum at the g
┴ 
region. A 5-line superhyperfine structure 
characteristic of the interaction with two equivalent nitrogen 
nuclei clearly appears. The superhyperfine splitting constant 
is equal to 13 gauss. Since the spectrum of [CuCl2(phen)] 
does not present a nitrogen resolved superhyperfine structure, 
this structure can be attributed to the second site, which 
corresponds to the Schiff base complexes.
Anti-Trypanosoma cruzi activity
The activity of the free Schiff bases, CuCl2.2H2O, 
[CuCl2(phen)] and Cu2+ complexes was assayed against 
bloodstream trypomastigotes of T. cruzi (Y strain). The 
EC50 values were determined and the results are presented 
in Table 2.
The Schiff bases, HL1 and HL2 and [CuCl2(phen)] 
presented a low to moderated effect on trypomastigotes 
of T. cruzi, showing EC50 values in the 7-40 µmol L-1 
range. The association between Cu2+, phen and the Schiff 
base in complex 2 did not lead to increased activity. 
However complex 1 showed an EC50 value equal to 
0.94 ± 0.17 µmol L-1 being approximately 7-fold times more 
potent than the free phen and 13-fold times more potent 
than the free Schiff base HL1 and Bnz (the reference drug), 
thus exhibiting a promising characteristic in the search for 
Table 1. EPR parameters of the two components, a and b (see Figure 2), 
of the Cu2+ complexes 1 and 2 in DMSO:MeOH, 1:1. The EPR parameters 
of the [CuCl2(phen)] precursor in DMSO are also listed for comparison
Solution (77 K) g┴ gІІ AII / gauss AN / gauss
[CuCl2(phen)] 2.074 2.292 155
Component a 2.070 2.291 154
Component b 2.070 2.324 148 13
g┴ and gІІ: the perpendicular and parallel components of the axially 
symmetric g tensor; AІІ: the parallel component of the hyperfine splitting 
constant from the copper nucleus I = 3/2; AN: the hyperfine splitting 
constant from two equivalent nitrogen nucleus.
Figure 2. EPR spectra of the complexes 1 and 2 in a mixture of methanol 
and DMSO (ca. 10-3 mol L-1) at 77 K. Parameters of components a and 
b appear in Table 1.
Table 2. Activity (mean ± SD) and selectivity index (SI) of the compounds 
and benznidazole (Bnz) on bloodstream trypomastigotes (BT) forms of 
T. cruzi (Y strain), in vitro (24 h of incubation at 310 K)
Compound EC50 / (µmol L-1)
Selectivity 
index (SI)
HL1 14 ± 5 0.7 
HL2 40 ± 22 2.4
[CuCl(L1)(phen)].0.5H2O 0.94 ± 0.17 4 
[CuCl(L2)(phen)].2H2O > 96 0.03
CuCl2.2H2O 82 ± 3 6
[CuCl2(phen)]6 7 ± 5 < 4
Bnz 13 ± 2 77
SD = standard deviation of multiple experimental measurements; 
SI: selective index: ratio between LC50/EC50 values; LC50: drug 
concentration that reduces by 50% the viability of the mammalian cell; 
EC50: drug concentration that reduces by 50% the number of parasites.
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new drugs with anti-Trypanosoma cruzi activity. However, 
all studied compounds also presented a cytotoxic effect 
on mammalian cells, leading to a low selectivity index as 
compared to the reference drug.
Antiproliferative activity
The antiproliferative activity of the free Schiff 
bases, the copper(II) complexes and doxorubicin, the 
reference drug, was evaluated using seven tumor cell lines 
U251 (melanoma), MCF7 (breast cancer), NCI/ADR-RES 
(resistant ovarian), 786-0 (kidney), NCI-H460 (lung), 
PC-3 (prostate), HT29 (colorectal) and the normal cell line 
HaCaT (Table 3).
All analyzed compounds showed cytostatic activity 
and in some cases there was also cytotoxic activity. The 
Cu2+ complexes were more active than their respectively 
free Schiff bases. Although the copper(II) complexes were 
less potent than the reference drug doxorubicin, they were 
active in low concentrations (lower than 2 µg mL-1) and 
had a selective index higher than the reference drug in 
the majority of cells tested. Thus the studied complexes 
manifested antitumor potential and are therefore efficacious 
candidates for in vivo tests. 
It is important to note that the anti-T. cruzi agent 
Nifurtimox has exhibited a promising antitumor effect on 
neuroblastoma32 and that other anti-T. cruzi candidates 
like the vanadyl complex, [VO(SO4)(H2O)2(dppz)].2H2O, 
that includes the bidentate polypyridyl DNA intercalator 
dipyrido[3,2-a:2’,3’-c]phenazine (dppz) has exhibited 
antitumor effects with EC50 values in the micromolar range.7
DNA binding studies
The intensity of the HL1, HL2, complexes 1 and 2 
absorption bands, in the presence of CT-DNA, resulted 
in a hypochromic effect, which supported the compound 
intercalation with CT-DNA.33 Figure 3 shows, as an 
example, the UV spectra of HL2 and complex 2, both in 
the absence of CT-DNA and the presence of increasing 
amounts of the latter.
The binding constant (Kb) values obtained for HL1, HL2 
and complexes 1 and 2 were in the 0.17-1.84 × 104 L mol-1 
range, suggesting moderate binding to CT-DNA, wherein 
complex 1 showed the higher Kb value (Table 4, Figure 3).12,34
The higher Kb value observed for complex 1 was 
in corroboration with its greater anti-T. cruzi and 
antiproliferative activities suggesting that DNA could be 
an important target for these two activities.
Fluorescence titration experiments were performed 
using ethidium bromide (EB) as a DNA-intercalator, thus 
forming the CT-DNA-EB complex, in order to provide more 
evidence for the interaction mode between HL1, HL2, 1 
and 2 with CT-DNA.27 The fluorescence emission spectra 
of the CT-DNA-EB complex was verified for an increase in 
compounds up to a 1:3 DNA:compound ratio. The addition 
of the Cu2+ complexes lead to an appreciable reduction 
in the CT-DNA-EB fluorescence absorption intensity, at 
λem = 607 nm (Figure 4).
The Ksv values were calculated by the ratio of the slope to 
the intercept in a plot of I0/I versus compound concentration 
and showed that the quenching of CT-DNA-EB, by the 
compounds, was in agreement with the linear Stern-Volmer 
equation (equation 2), indicating that EB was replaced in 
the CT-DNA-EB complex by each compound resulting 
in a decrease in the fluorescence intensity. The results 
demonstrated that CT-DNA binding affinity was higher 
for compound 1, followed by 2, HL1 and HL2, which is 
in agreement with the calculated Kb values (see Table 4).
Albumin binding studies 
The fluorescence quenching spectra of bovine serum 
albumin (BSA) and human serum albumin (HSA) were 
Table 3. The effect of free Schiff bases, their copper(II) complexes, [CuCl2(phen)] and doxorubicin (the reference drug) on tumor cell lines (IC50, µg mL-1) 
and the selective index (SI) in parenthesis
IC50 (SI) / (µg mL-1)
Compound U251 MCF7 NCI/ADR-RES 786-0 NCI-H460 PC-3 HT29
HL1 2.4 (1.1) 3.0 (0.9) 3.1 (0.8) 20.30 (0.1) 3.3 (0.8) 2.5 (1.0) 1.5 (1.7)
HL2 9.2 (1.8) 3.1 (5.3) 17.1 (1.0) 25.0 (0.7) 16.7 (1.0) 24.1 (0.7) 4.4 (3.8)
1 0.2 (3.1) 0.5 (1.2) 1.3 (0.5) 1.573 (0.4) 0.29 (2.1) 0.26 (2.3) 0.50 (1.2)
2 0.5 (3.2) 1.9 (0.8) 1.6 (1.0) 1.495 (1.1) 0.3 (5.3) − 1.0 (1.6)
[CuCl2(phen)] 0.3 (0.2) 0.8 (0.6) 0.6 (0.4) 0.3 (0.2) 1.0 (0.8) 0.6 (0.4) 1.4 (1.0)
Doxorubicin 0.029 (2.0) 0.024 (2.4) 0.27 (0.2) 0.059 (1.0) 0.025 (2.3) 0.18 (0.3) 0.18 (0.3)
U251: human tumor cell lines (glioma); MCF-7: breast; NCI-ADR/RES: ovarian expressing a resistant phenotype to adryamycin; 786-0: kidney; 
NCI-H460: lung, non-small cells; PC-3: prostate; HT-29: colon; HL1: 2-((5-nitrofuran-2-yl)methyleneamino)phenol; HL2: 2-(4-nitrobenzylideneamino)
phenol.
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monitored in the presence of increasing amounts of the HL1, 
HL2, complexes 1 and 2. BSA had a strong fluorescence 
emission peak at 342 nm after being excited at a wavelength 
of 285 nm, while HSA had a fluorescence emission peak at 
334 nm after being excited at 280 nm.28 The fluorescence 
intensity of BSA and HSA decreased in the presence of the 
Schiff bases and their Cu2+ complexes. Upon addition of HL1, 
HL2, complexes 1 and 2 the fluorescence intensities of BSA 
and HSA, taking into consideration a 2:1 compound:albumin 
ratio, decreased by 4.42% (HL1:BSA), 29.3% (HL2:BSA), 
18.3% (1:BSA), 13.3% (2:BSA), 8.3% (HL1:HSA), 6.8% 
(HL2:HSA), 26.2% (1:HSA) and 8.9% (2:HSA). The results 
suggested that all the studied compounds could interact with 
these proteins.31 Figure 5 shows, as an example, the BSA 
emission spectra in the presence of HL1 and complex 1, 
while Figure 6 shows the Stern-Volmer plots for complexes 1 
and 2 in the presence of BSA and HSA. The calculated KSV 
values are listed in Table 5.
The values of the interaction constants between the 
free Schiff bases and their Cu2+ complexes with BSA 
were in the 0.44-3.14 × 105 L mol-1 range and with HSA 
were in the 0.18-2.43 × 105 L mol-1 range, indicating a 
moderate interaction with BSA and HSA for all the studied 
compounds. The interaction between a drug and albumins 
can occur by a static or a dynamic process28 and one form of 
distinguishing between them is to calculate the bimolecular 
quenching rate constant, kq (equation 3). The kq values 
obtained for the free Schiff bases and their Cu2+ complexes 
were in the 1012-1013 L mol-1 s-1 range, which was far greater 
than the upper limit of 2.0 × 1010 L mol-1 s-1,28,35 suggesting 
that fluorescence quenching of the serum albumins by the 
Figure 3. The UV spectra in the absence (dashed lines) and presence of CT-DNA at increasing amounts and the [DNA]/(εa – εf) versus [DNA] plot for 
(a) HL2 and (b) complex 2 in a buffer solution of pH 7.4.
Table 4. The Kb (L mol-1) and the Ksv (L mol-1) values for the interaction 
between the Schiff bases and copper(II) complexes to CT-DNA and 
CT-DNA-EB
Compound Kb 10
4
 / 
(L mol-1) R
2 Ksv 104 / 
(L mol-1) R
2
HL1 0.79 0.999 4.29 0.979
HL2 0.17 0.993 4.13 0.981
1 1.84 0.999 5.36 0.980
2 0.89 0.999 4.52 0.976
HL1: 2-((5-nitrofuran-2-yl)methyleneamino)phenol; HL2: 2-(4-nitro-
benzylideneamino)phenol.
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Schiff bases and Cu2+ complexes was predominantly a static 
process, which requires the quencher to bind to albumin 
near the Trp residues, with the resulting formation of a 
non-fluorescent compound.28
Conclusions
The nitroaromatic Schiff bases HL1 and HL2 
coordinated to Cu2+ in a bidentate mode forming the 
monomeric pentacoordinated [CuCl(L1)(phen)].0.5H2O (1) 
and [CuCl(L2)(phen)].2H2O (2) complexes. Complex 1, 
which contains the nitrofuran derivative HL1, showed 
antichagasic activity while 2, which contained the 
nitrobenzene derivative HL2, was not active. Complexes 1 
and 2 also presented antiproliferative activities in 
doses lower than 2 µg L-1, being more potent than their 
correspondent Schiff bases. The Schiff bases and their Cu2+ 
complexes could interact with CT-DNA and displace EB 
from the CT-DNA-EB complex, suggesting an intercalative 
mode of interaction. Complex 1, which was the most active 
against T. cruzi and presented a good antiproliferative 
active, showed also the highest binding affinity with 
CT-DNA, suggesting that DNA can be an important target 
Figure 4. (a) The fluorescence spectra of CT-DNA-EB in the absence (dashed line) and presence of complex 1 in increasing amounts; (b) plot of CT-
DNA-EB relative fluorescence intensity at λexc = 545 nm (%) versus r (r = [compound]/[CT-DNA]) in the presence of HL1, HL2, 1 and 2 (up to 52% of 
the initial CT-DNA-EB fluorescence intensity for HL1, 53% for HL2, 46% for 1 and 49% for 2), phosphate buffer at pH 7.4.
Table 5. The Ksv (L mol-1) values for the interaction between the Schiff 
bases and copper(II) complexes to albumins
Compound
BSA HSA
Ksv 105 / 
(L mol-1) R
2 Ksv 105 / 
(L mol-1) R
2
HL1 0.44 0.980 0.38 0.949
HL2 3.14 0.968 0.18 0.971
1 1.99 0.973 2.43 0.998
2 1.35 0.986 0.43 0.990
BSA: bovine serum albumins; HSA: and human serum albumins; 
HL1: 2-((5-nitrofuran-2-yl)methyleneamino)phenol; HL2: 2-(4-nitro-
benzylideneamino)phenol.
Figure 5. The BSA emission spectra (2 µmol L-1) in the absence and presence of (a) HL1 (0-9.1 µmol L-1) and (b) complex 1 (0-5.7 µmol L-1).
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for anti-T. cruzi and antiproliferative activities. All the 
studied compounds presented moderate binding properties 
to albumins.
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Supplementary data are available free of charge at 
http://jbcs.sbq.org.br as PDF file.
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